Development of a label-free LC-MS/MS strategy to approach the identification of candidate protein biomarkers of disease recurrence in prostate cancer patients in a clinical trial of combined hormone and radiation therapy.
Morrissey, Brian O'Shea, Carmel Armstrong, John Rooney, Cathy Staunton, Lisa Sheehan, Martina Shannon, Aoife M Pennington, Stephen R
Morrissey, Brian
O'Shea, Carmel
Armstrong, John
Rooney, Cathy
Staunton, Lisa
Sheehan, Martina
Shannon, Aoife M
Pennington, Stephen R
Advisors
Editors
Other Contributors
Date
2013-06
Date Submitted
Keywords
PROSTATE CANCER
Other Subjects
RADIATION THERAPY
HORMONE THERAPY
HORMONE THERAPY
Subject Mesh
Antineoplastic Agents, Hormonal
Blood Proteins
Chromatography, High Pressure Liquid
Combined Modality Therapy
Humans
Male
Nanotechnology
Principal Component Analysis
Prostatic Neoplasms
Recurrence
Tandem Mass Spectrometry
Time Factors
Trypsin
Tumor Markers, Biological
Blood Proteins
Chromatography, High Pressure Liquid
Combined Modality Therapy
Humans
Male
Nanotechnology
Principal Component Analysis
Prostatic Neoplasms
Recurrence
Tandem Mass Spectrometry
Time Factors
Trypsin
Tumor Markers, Biological
Planned Date
Start Date
Collaborators
Principal Investigators
Alternative Titles
Publisher
Abstract
Combined hormone and radiation therapy (CHRT) is one of the principle curative regimes for localised prostate cancer (PCa). Following treatment, many patients subsequently experience disease recurrence however; current diagnostics tests fail to predict the onset of disease recurrence. Biomarkers that address this issue would be of significant advantage.
Language
en
ISSN
1862-8354
eISSN
ISBN
DOI
10.1002/prca.201300004
PMID
23670859